Vaccine. 2002 Jan 15;20(7-8):1039-45.

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV.

Source

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK. sarah.gilbert@well.ox.ac.uk

Abstract

Recombinant replication-defective adenovirus expressing the CS gene from Plasmodium berghei (Ad-PbCS) was found to induce a strong CD8(+) T cell response after intra-dermal or -muscular immunisation. Boosting of an adenovirus-primed immune response with the replication-impaired poxvirus, modified vaccinia virus Ankara (MVA) led to enhanced immunogenicity and substantial protective efficacy. The recombinant adenoviral vaccine was capable of boosting to protective levels a CD8(+) T cell response primed by either a plasmid DNA vaccine, a recombinant Ty virus-like particle vaccine or recombinant MVA each expressing the same epitope or antigen. Complete protective efficacy after intradermal immunisation was observed with the adenovirus prime-MVA boost regime. This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses.

PMID:: 11803063; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. [Vaccine. 1999]
Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
Dégano P, Schneider J, Hannan CM, Gilbert SC, Hill AV. Vaccine. 1999 Nov 12; 18(7-8):623-32.
Review Progress in DNA-based heterologous prime-boost immunization strategies for malaria. [Immunol Rev. 2004]
Review Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
Moore AC, Hill AV. Immunol Rev. 2004 Jun; 199:126-43.
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. [Nat Med. 1998]
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Nat Med. 1998 Apr; 4(4):397-402.
Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. [Vaccine. 2000]
Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.
Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F. Vaccine. 2000 Mar 6; 18(17):1863-9.
Review DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. [Dev Biol (Basel). 2000]
Review DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
Hill AV, Reece W, Gothard P, Moorthy V, Roberts M, Flanagan K, Plebanski M, Hannan C, Hu JT, Anderson R, et al. Dev Biol (Basel). 2000; 104:171-9.

See reviews... See all...

Cited by 27 PubMed Central articles

Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. [Infect Immun. 2011]
Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.
Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araújo AF, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM. Infect Immun. 2011 May; 79(5):2120-30. Epub 2011 Feb 28.
Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques. [Malar J. 2011]
Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques.
Hamid MM, Remarque EJ, El Hassan IM, Hussain AA, Narum DL, Thomas AW, Kocken CH, Weiss WR, Faber BW. Malar J. 2011 Feb 8; 10(1):29. Epub 2011 Feb 8.
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. [Clin Infect Dis. 2011]
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, et al. Clin Infect Dis. 2011 Jan 1; 52(1):1-7.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria mo...
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.
Vaccine. 2002 Jan 15 ;20(7-8):1039-45.

PubMed
Quantitative real-time polymerase chain reaction for malaria diagnosis and its u...
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
Am J Trop Med Hyg. 2005 Jul ;73(1):191-8.

PubMed
Prime boost vaccines power up in people.
Prime boost vaccines power up in people.
Nat Med. 2003 Jun ;9(6):642-3.

PubMed
Cellular immune responses induced in cattle by heterologous prime-boost vaccinat...
Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.
Immunology. 2004 Jul ;112(3):461-70.

PubMed
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot a...
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.
J Immunol. 2005 Nov 1 ;175(9):5675-80.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Cited by 27 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information